LUCIUS 卢修斯 吉瑞替尼 Gilteritinib急性髓系 白血病

吉瑞替尼

美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品

Gilteritinib

老挝国家食药监局批准上市
老挝国家药检所检测认证

急性髓系

Composmeni
Each LuciCl tablel contains: 44.2mng Ciltentinib

LUCiUS

Fumarate eaursalent to Giltanifinh

PHARMACEUTICALS

Indication:
LuciGilis a kinase inbibitor indieated for the

90 Tablets

白血病

treatment of adult patients who have relapsed or
refractory acute mveloid lenkemia (AM Ynith
FL.T3 mutation as detected by an FDA-approved
Dosage and s
The recommended starting dose of LuciGil is 120
mg orally once darly with or without food. In the

LUCIGIL

progression or unacceptable
foxicity freatment fora minimum of 6 months
recommiended te allow time for a clinical

Gilteritinib Tablets

mum of o montns
Tablet shoold be swallowed whole & not chewed

FDA批准

or crushed.
Storages ina dry place and store ar 20°℃ to 25°C.

40mg

Keep medicine out of the reach of Children. Do
not administerell
not admimstered LacnGil in Pregnancy an
PLEASE SEE PACKAGE INSERT
Manufactured and Marketed by
LUCIUS
PAMENACEITCALS

权威认证

Thongmang village. Xaythany district.
Vientiane Capital, Laos
wWW.CTUS.Ia
warning: To be sold by retail on nroedhnden
of a Registered oncologist only, and es diteeta
y the physician.

Rx only

口碑质量

适应症:

适用于治疗采用经充分验证的检测方法检测到携带

FMS样酪氨酸激酶3(FLT3)突变的复发性或难治性急性
髓系白血病(AML)成人患者。

推荐剂量:

每天口服一次,每次120mg。